BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boëlle PY, Debray D, Guillot L, Corvol H; French CF Modifier Gene Study Investigators. SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genet Med 2019;21:2151-5. [PMID: 30739910 DOI: 10.1038/s41436-019-0449-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Fawcett KA, Song K, Qian G, Farmaki AE, Packer R, John C, Shrine N, Granell R, Ring S, Timpson NJ, Yerges-Armstrong LM, Eastell R, Wain LV, Scott RA, Tobin MD, Hall IP. Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank. ERJ Open Res 2021;7:00049-2021. [PMID: 33981765 DOI: 10.1183/23120541.00049-2021] [Reference Citation Analysis]
2 Tiensuu H, Haapalainen AM, Tissarinen P, Pasanen A, Määttä TA, Huusko JM, Ohlmeier S, Bergmann U, Ojaniemi M, Muglia LJ, Hallman M, Rämet M. Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth. BMC Med 2022;20:141. [PMID: 35477570 DOI: 10.1186/s12916-022-02339-8] [Reference Citation Analysis]
3 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
4 Sharma N, Cutting GR. The genetics and genomics of cystic fibrosis. J Cyst Fibros 2020;19 Suppl 1:S5-9. [PMID: 31879237 DOI: 10.1016/j.jcf.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Raynal C, Corvol H. Variant classifications, databases and genotype-phenotype correlations. Arch Pediatr 2020;27 Suppl 1:eS13-8. [PMID: 32172930 DOI: 10.1016/S0929-693X(20)30045-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]
8 Dai W, Tang T, Dai Z, Shi D, Mo L, Zhang Y. Probing the Mechanism of Hepatotoxicity of Hexabromocyclododecanes through Toxicological Network Analysis. Environ Sci Technol 2020;54:15235-45. [DOI: 10.1021/acs.est.0c03998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Walton NI, Zhang X, Soltis AR, Starr J, Dalgard CL, Wilkerson MD, Conrad D, Pollard HB. Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients. Physiol Rep 2021;9:e14886. [PMID: 34086412 DOI: 10.14814/phy2.14886] [Reference Citation Analysis]
10 Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol 2021:S0168-8278(21)02227-3. [PMID: 34848258 DOI: 10.1016/j.jhep.2021.11.022] [Reference Citation Analysis]
11 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
12 Dana J, Girard M, Debray D. Hepatic manifestations of cystic fibrosis. Curr Opin Gastroenterol 2020;36:192-8. [PMID: 32097175 DOI: 10.1097/MOG.0000000000000624] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Schwantes-An TH, Darlay R, Mathurin P, Masson S, Liangpunsakul S, Mueller S, Aithal GP, Eyer F, Gleeson D, Thompson A, Muellhaupt B, Stickel F, Soyka M, Goldman D, Liang T, Lumeng L, Pirmohamed M, Nalpas B, Jacquet JM, Moirand R, Nahon P, Naveau S, Perney P, Botwin G, Haber PS, Seitz HK, Day CP, Foroud TM, Daly AK, Cordell HJ, Whitfield JB, Morgan TR, Seth D; GenomALC Consortium. Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology 2021;73:1920-31. [PMID: 32853455 DOI: 10.1002/hep.31535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
14 Zhang Y, Zeng F, Zeng M, Han X, Cai L, Zhang J, Weng J, Gao Y. Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. Int J Biol Sci 2021;17:3554-72. [PMID: 34512165 DOI: 10.7150/ijbs.62168] [Reference Citation Analysis]
15 Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros 2020;19 Suppl 1:S10-4. [PMID: 31734115 DOI: 10.1016/j.jcf.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]